Neurocrine Biosciences Inc NBIX
We take great care to ensure that the data presented and summarized in this overview for NEUROCRINE BIOSCIENCES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NBIX
View all-
Black Rock Inc. New York, NY14.2MShares$1.65 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.17 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$535 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$287 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$274 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.9MShares$221 Million4.37% of portfolio
-
Geode Capital Management, LLC Boston, MA1.82MShares$211 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.8MShares$209 Million0.03% of portfolio
-
Morgan Stanley New York, NY1.54MShares$179 Million0.02% of portfolio
-
Eaton Vance Management Boston, MA1.35MShares$157 Million0.21% of portfolio
Latest Institutional Activity in NBIX
Top Purchases
Top Sells
About NBIX
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL ? Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Insider Transactions at NBIX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 03
2024
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
1,295
-77.45%
|
$146,335
$113.66 P/Share
|
Sep 13
2024
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
3,461
-67.43%
|
$418,781
$121.88 P/Share
|
Aug 15
2024
|
William H Rastetter Director |
SELL
Open market or private sale
|
Direct |
14,250
-27.54%
|
$2,080,500
$146.69 P/Share
|
Aug 13
2024
|
Gary A Lyons Director |
SELL
Open market or private sale
|
Direct |
11,570
-8.86%
|
$1,735,500
$150.43 P/Share
|
Aug 13
2024
|
Gary A Lyons Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,570
+8.14%
|
$485,940
$42.76 P/Share
|
Aug 13
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,100
-30.9%
|
$2,115,000
$150.38 P/Share
|
Aug 13
2024
|
Matt Abernethy Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,100
+23.61%
|
$1,029,300
$73.6 P/Share
|
Aug 13
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
7,143
-46.79%
|
$1,071,450
$150.11 P/Share
|
Aug 13
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,043
+23.97%
|
$313,429
$103.52 P/Share
|
Aug 06
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
273
-3.97%
|
$40,131
$147.7 P/Share
|
Aug 06
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
273
+3.82%
|
$21,567
$79.02 P/Share
|
Aug 01
2024
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
12,632
-40.97%
|
$1,932,696
$153.26 P/Share
|
Aug 01
2024
|
Julie Cooke Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,632
+29.06%
|
$770,552
$61.82 P/Share
|
Aug 01
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,996
-7.01%
|
$461,384
$154.01 P/Share
|
Aug 01
2024
|
Darin Lippoldt Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,996
+6.55%
|
$236,684
$79.02 P/Share
|
Jul 16
2024
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
900
-4.71%
|
$135,000
$150.04 P/Share
|
Jul 16
2024
|
Julie Cooke Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+4.5%
|
$54,900
$61.82 P/Share
|
Jul 16
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
2,857
-11.41%
|
$428,550
$150.05 P/Share
|
Jul 16
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,957
+9.74%
|
$201,571
$103.52 P/Share
|
Jul 16
2024
|
Gary A Lyons Director |
SELL
Open market or private sale
|
Direct |
930
-0.78%
|
$139,500
$150.03 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 873K shares |
---|
Open market or private sale | 949K shares |
---|---|
Bona fide gift | 2.75K shares |